El texto completo de este artículo está disponible en PDF.
SARS-CoV-2 elicits both cellular and antibody immune responses.
Hundreds vaccines have been developed using different platforms.
COVID-19 vaccination has began in some countries under emergency use authorization.
SARS-CoV-2 mutations and genetic variability may enhance viruses transmissibility and impact vaccines effectivity.
Host genetic variability may be related to SARS-CoV-2 susceptibility and severity.
Coronavirus disease 19 (COVID-19) continues to challenge most scientists in the search of an effective way to either prevent infection or to avoid spreading of the disease. As result of global efforts some advances have been reached and we are more prepared today than we were at the beginning of the pandemic, however not enough to stop the transmission, and many questions remain unanswered. The possibility of reinfection of recovered individuals, the duration of the immunity, the impact of SARS-CoV-2 mutations in the spreading of the disease as well as the degree of protection that a potential vaccine could have are some of the issues under debate. A number of vaccines are under development using different platforms and clinical trials are ongoing in different countries, but even if they are licensed it will need time until reach a definite conclusion about their real safety and efficacy. Herein we discuss the different strategies used in the development of COVID-19 vaccines, the questions underlying the type of immune response they may elicit, the consequences that new mutations may have in the generation of sub-strains of SARS-CoV-2 and their impact and challenges for the efficacy of potential vaccines in a scenario postpandemic.El texto completo de este artículo está disponible en PDF.
Keywords : Reinfection, Spike protein, Long-term immunity, T-cell response, Mutation